glp-1 drugs and breast cancer GLP-1s: Weight Loss Survival in Recovery glp-1 drugs and breast cancer

The glucagon-like peptide-1 receptor in the ventromedial hypothalamus reduces short-term food intake in male mice by regulating nutrient sensor activity

In an analysis of more than 6,800 colon cancer patients across all University of California Health sites, researchers found that those taking glucagon-like peptide-1 (GLP-1) medications were less than half as likely to die within five years compared to those who werent on the drugs (15.5% vs

Ongoing trials targeting this population reflect how suitable it is

It can not only be used as a liver protecting agent, but also as a feed additive

Preprint at (2016)

S Karger, 112-136, 1994